Voyager Therapeutics (FRA:VT6) GF Value Rank: 1 (As of Jul. 12, 2026) — 50% Below Median


FRA:VT6 Voyager Therapeutics Inc FRA:VT6
52 GF Score
Price €3.06
GF Value €1.47
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics GF Value Rank?

Voyager Therapeutics FRA:VT6 -2.05% 52 GF Value Rank is 1 as of Jul. 12, 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates FRA:VT6 with a GF Score™ of 52/100 and a GF Value™ of €1.47 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Voyager Therapeutics has the GF Value Rank of 1.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Voyager Therapeutics GF Value Rank Related Terms


FRA:VT6 vs KROS, CDXS, CAMP: GF Value Rank Comparison

For the Biotechnology subindustry, Voyager Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's GF Value Rank falls into.


FRA:VT6
52GF Score
Voyager Therapeutics Inc FRA:VT6
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 1 mean?
Voyager Therapeutics (FRA:VT6) has a GF Value Rank of 1 as of Jul. 12, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Voyager Therapeutics and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, Voyager Therapeutics' GF Value Rank has ranged from 1.00 to 10.00.
Is Voyager Therapeutics' GF Value Rank too high?
Voyager Therapeutics' current GF Value Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Voyager Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' GF Value Rank compare to KROS and CDXS?
Voyager Therapeutics' GF Value Rank of 1 can be compared against companies in the Biotechnology industry. Historically, Voyager Therapeutics' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current GF Value Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.47, compared to a current price of €3.06 — trading 107.9% above its estimated fair value. The current GF Value Rank is 1, which is 50% below median its 10-year median of 2.00. Voyager Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current GF Value Rank is 1 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.06 is trading 107.9% above its estimated GF Value™ of €1.47. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • GF Value Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: €1.47 vs. price of €3.06 (107.9% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score

Get the complete analysis for FRA:VT6

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€1.47
GF Value